Akari Therapeutics (AKTX) Cash from Operations (2014 - 2026)
Akari Therapeutics (AKTX) posted quarterly Cash from Operations of 2488000.0 for Q1 2026, down 15.72% year-on-year from 2952097.13 in Q1 2025, and up 18.18% on a QoQ basis from 3041000.0 in Q4 2025.
Akari Therapeutics (AKTX) Cash from Operations (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Cash from Operations for 9 consecutive years, with 2488000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Operations fell 15.72% year-over-year to 2488000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10906000.0 (down 2.33% YoY) and the FY2025 annual result came in at 10568000.0, up 15.81% from the prior year.
- Cash from Operations improved to 2488000.0 in Q1 2026 per AKTX's latest filing, from 3041000.0 in the prior quarter.
- Over the last five years, Cash from Operations for AKTX reached as high as 1490000.0 in Q3 2024 and fell as low as 4894000.0 in Q2 2024.
- A 4-year average of 3233846.15 and a median of 3041000.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 51.83% — and 2025, when it slumped 43.17%.
- Year by year, Cash from Operations stood at 4409000.0 in 2023, then jumped by 51.83% to 2124000.0 in 2024, then sank by 43.17% to 3041000.0 in 2025, then climbed by 18.18% to 2488000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 2488000.0, 3041000.0, and 2121000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | -2.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.49 Mn |
| Mar 31, 2026 | -2.49 Mn |
| Dec 31, 2025 | -3.04 Mn |
| Dec 31, 2025 | -3.04 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -3.26 Mn |
| Jun 30, 2025 | -3.26 Mn |
| Mar 31, 2025 | -2.15 Mn |
| Mar 31, 2025 | -2.15 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Dec 31, 2024 | -2.12 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Sep 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -4.89 Mn |
| Jun 30, 2024 | -4.89 Mn |
| Mar 31, 2024 | -4.04 Mn |
| Mar 31, 2024 | -4.04 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Dec 31, 2023 | -4.41 Mn |